A UK NEQAS ISH Multicenter Ring Study Using the VentanaHER2Dual-Color ISH Assay-Reference-Cited by-同舟云学术

A UK NEQAS ISH Multicenter Ring Study Using the VentanaHER2Dual-Color ISH Assay

Published:2011-01 Issue:1 Volume:135 Page:157-162
ISSN:0002-9173
Container-title:American Journal of Clinical Pathology
language:en
Short-container-title:Am J Clin Pathol

Author:

Bartlett J.M.S.,Campbell Fiona M.,Ibrahim Merdol,O’Grady Anthony,Kay Elaine,Faulkes Catherine,Collins Nadine,Starczynski Jane,Morgan John M.,Jasani Bharat,Miller Keith

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Link

http://academic.oup.com/ajcp/article-pdf/135/1/157/18133394/ajcpath135-0157.pdf

Reference19 articles.

1. HER2 testing in the UK: further update to recommendations

2. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

3. Pharmacodiagnostic Testing in Breast Cancer

4. Faratian D Bartlett J . Predictive markers in breast cancer: the future. Histopathology. 2008;52:91–98.

5. External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Analysis of HER2 Immunohistochemistry (IHC) and Brightfield Dual-Color In Situ Hybridization (DISH) in Lymph Node Metastasized Breast Cancer;2024-09-04

2. Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer;Laboratory Investigation;2024-01

3. Efficient Convolution Network to Assist Breast Cancer Diagnosis and Target Therapy;Cancers;2023-08-06

4. Detection of ERBB2 and CEN17 signals in fluorescent in situ hybridization and dual in situ hybridization for guiding breast cancer HER2 target therapy;Artificial Intelligence in Medicine;2023-07

5. Decision Theory versus Conventional Statistics for Personalized Therapy of Breast Cancer;Journal of Personalized Medicine;2022-04-02